Phathom Pharmaceuticals, Inc. Operating CF per Share

Operating CF per Share of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF per Share growth rates and interactive chart. Total operating cash flow in a period divided by the weighted average number of shares outstanding. A company with $100 million in operating cash flow and 10 million weighted average shares will have operating cash flow per share of $10.


Highlights and Quick Summary

  • Operating CF per Share for the quarter ending June 29, 2021 was -0.77 (a -43.53% decrease compared to previous quarter)
  • Year-over-year quarterly Operating CF per Share increased by 24.63%
  • Annual Operating CF per Share for 2020 was -2.09 (a 41.43% increase from previous year)
  • Annual Operating CF per Share for 2019 was -1.48 (a 3445.56% increase from previous year)
  • Twelve month Operating CF per Share ending June 29, 2021 was -3.46 (a 16.56% increase compared to previous quarter)
  • Twelve month trailing Operating CF per Share increased by 78.09% year-over-year
Trailing Operating CF per Share for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-3.46 -2.97 -2.04 -1.94
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF per Share of Phathom Pharmaceuticals, Inc.

Most recent Operating CF per Shareof PHAT including historical data for past 10 years.

Interactive Chart of Operating CF per Share of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Operating CF per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.77 -1.37
2020 -0.82 -0.62 -0.28 -0.35 -2.09
2019 -2.06 -0.97 -0.78 -0.12 -1.48
2018 0.0 -0.11 -0.04

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.